Immutep Limited ADR (NASDAQ: IMMP)’s stock price has decreased by -6.12 compared to its previous closing price of 1.96. However, the company has seen a -11.96% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-15 that Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031.
Is It Worth Investing in Immutep Limited ADR (NASDAQ: IMMP) Right Now?
The stock has a 36-month beta value of 2.22. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMMP is 141.20M, and at present, short sellers hold a 3.55% of that float. On November 22, 2024, the average trading volume of IMMP was 114.02K shares.
IMMP’s Market Performance
The stock of Immutep Limited ADR (IMMP) has seen a -11.96% decrease in the past week, with a -4.66% drop in the past month, and a -24.28% fall in the past quarter. The volatility ratio for the week is 6.08%, and the volatility levels for the past 30 days are at 5.24% for IMMP. The simple moving average for the past 20 days is -3.85% for IMMP’s stock, with a -21.46% simple moving average for the past 200 days.
Analysts’ Opinion of IMMP
Many brokerage firms have already submitted their reports for IMMP stocks, with CapitalOne repeating the rating for IMMP by listing it as a “Overweight.” The predicted price for IMMP in the upcoming period, according to CapitalOne is $10 based on the research report published on May 17, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see IMMP reach a price target of $7. The rating they have provided for IMMP stocks is “Outperform” according to the report published on August 03rd, 2023.
Ladenburg Thalmann gave a rating of “Buy” to IMMP, setting the target price at $8.30 in the report published on August 03rd of the previous year.
IMMP Trading at -10.03% from the 50-Day Moving Average
After a stumble in the market that brought IMMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.83% of loss for the given period.
Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 6.08%, as shares sank -2.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.04% lower at present.
During the last 5 trading sessions, IMMP fell by -11.96%, which changed the moving average for the period of 200-days by -14.81% in comparison to the 20-day moving average, which settled at $1.9138. In addition, Immutep Limited ADR saw -23.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IMMP
Current profitability levels for the company are sitting at:
- -16.18 for the present operating margin
- -3.07 for the gross margin
The net margin for Immutep Limited ADR stands at -10.95. The total capital return value is set at -0.48. Equity return is now at value -25.75, with -24.05 for asset returns.
Based on Immutep Limited ADR (IMMP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.13. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -2544.13.
Currently, EBITDA for the company is -44.54 million with net debt to EBITDA at 2.52. When we switch over and look at the enterprise to sales, we see a ratio of 44.23. The receivables turnover for the company is 0.75for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.25.
Conclusion
To sum up, Immutep Limited ADR (IMMP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
